Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females

Gynecological Endocrinology

Volumn 23, Issue 5, 2007, Pages 290-294

  Potolog Nahari, Claris ^a,b,c   Fishman, Ami ^a   Cohen, Ilan ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemotherapy; Ovarian protection; Young patients

Indexed keywords

BLEOMYCIN; CETRORELIX; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ESTRADIOL; ETOPOSIDE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LUTEINIZING HORMONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; B CELL LYMPHOMA; BREAST CANCER; CANCER THERAPY; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE STERILITY; FOLLITROPIN BLOOD LEVEL; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION; NONHODGKIN LYMPHOMA; OVARY FUNCTION; OVULATION INDUCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HORMONE ANTAGONISTS; HUMANS; INFERTILITY, FEMALE; LYMPHOMA; OVARY; PROSPECTIVE STUDIES;

EID: 34250209843     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701327661     Document Type: Article

References (22)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Oktay KH, Yih M. Preliminary experience with orthotopic and heterotopic transplantation of ovarian cortical strips. Semin Reprod Med 2002;20:63-74.
3. Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990;40:355-367.
4. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729.
5. Tauchmanova L, Selleri C, Rosa GD, Pagano L, Orio F, Lombardi G, Rotoli B, Colao A. High prevalence of endocrine dysfunction in long-term survivors after allogenic bone transplantation for hematologic diseases. Cancer 2002;95:1076-1084.
6. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005;17:299-308.
7. Rose DP, Davis TE. Ovarian function in patients receiving adjuvant chemotherpy for breast cancer. Lancet 1997;1:1174-1176.
8. Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in Hodgkin's disease. II. Effect on sexual function. J Am Med Assoc 1979;242:1882-1884.
9. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, Holmes, GF, Holmes FF, Latourette HB, Meigs JW, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.
10. Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 2003;18:90-95.
11. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620-1626.
12. Blumenfeld Z, Avivi I, Ritter M, Rowe JM. Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 1999;6:229-239.
13. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000;9:401-405.
14. Blumenfeld Z, Dann E, Avivi I, Epelbaum R, Rowe JM. Fertility after treatment for Hodgkin's disease. Ann Oncol 2003;13(Suppl 1):138-147.
15. Recchia F, Sica G, De Filippis S, Saggio G, RosselliM, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 2002;13:417-424.
16. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, Rea S. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-523.
17. Blumenfeld Z. Gynaecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003;15:359-370.
18. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonist and GnRH antagonist for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004;1:90-92.
19. Snajderova M. Drug combo preserves fertility during cancer treatment. Paper presented at: Endocrine Society 87th Annual Meeting; 2005 Jun 4-7; San Diego, CA.
20. Oktay K, Sonmezer M, Oktem O. Ovarian cryopreservation versus ovarian suppression by GnRH analogues: primum non nocere. Human Reprod 2004;19:1681-1683.
21. Ataya K, Moghissi K. Chemotherapy-induced premature ovarian failure: mechanisms and prevention. Steroids 1989;5:607-626.
22. Bokser L, Band S, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990;61:861-865.